Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Small Cell Lung Carcinoma 27Lymphoma, Large B-Cell, Diffuse 10Lung Neoplasms 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Lymphoma, Non-Hodgkin 6Lymphoma, B-Cell 6Hodgkin Disease 6Burkitt Lymphoma 6Neuroblastoma 5Medulloblastoma 5Neoplasms, Germ Cell and Embryonal 4Leukemia, Myeloid, Acute 4Small Cell Lung Cancer Extensive Stage 3Seminoma 3Retinoblastoma 3Recurrence 3Ovarian Neoplasms 3Multiple Myeloma 3Lymphoma 3Carcinoma, Neuroendocrine 3Brain Neoplasms 3Wilms Tumor 2Urinary Bladder Neoplasms 2Teratoma 2Sarcoma, Ewing 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Plasmablastic Lymphoma 2Neuroectodermal Tumors, Primitive 2Lymphoma, T-Cell 2Lymphoma, Mantle-Cell 2

Interventions

apatinib 1Etoposide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × HER2-negative Breast Cancer Brain Metastases × Etoposide × Clear all
NCT06418594 2024-12-10

Adebrelimab Plus Apatinib and Etoposide for the Treatment of HER2-Negative Breast Cancer Brain Metastasis

Beijing 302 Hospital

Phase 2 Recruiting
30 enrolled
Breast

HER2-negative Breast Cancer Brain Metastases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡